edobacomab
mAbexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Lipopolysaccharide (LPS)INHIBITOR
Lipopolysaccharide (LPS) inhibitor
Lipopolysaccharide (LPS) other
Inhibits priming effect of lipopolysaccharide (LPS) on the release of reactive oxygen species. Enhances classical-pathway complement fixation.
Although endotoxins vary across gram-negative species, it has been demonstrated in vitro to react wi
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108378 ↗
Also known as
- e5
- e5
- e5 monoclonal antibody
- edobacomab
- edobacomab
- xomen
- xomen-e5
- xomen-e5